Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04422210 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04422210 is a Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 2 participants.
The verdict
NCT04422210, a Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.
Interventions
- DRUG Venetoclax
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2020-11-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04422210
The ClinicalTrials.gov registry entry for NCT04422210 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Venetoclax is the first listed.
NCT04422210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04422210 about?
NCT04422210 is a clinical study titled "A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).". A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.
What is the current status of trial NCT04422210?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2020-09-22. Estimated completion is 2020-11-06.
What interventions are being tested in trial NCT04422210?
The interventions under investigation include: Venetoclax (DRUG), Carboplatin (DRUG), Atezolizumab (DRUG), Etoposide (DRUG).
Who is sponsoring clinical trial NCT04422210?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.